<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654121</url>
  </required_header>
  <id_info>
    <org_study_id>EVDM IT 001</org_study_id>
    <nct_id>NCT00654121</nct_id>
  </id_info>
  <brief_title>Prevention of Clinical Onset of Type 1 Diabetes in High Risk First Degree Relatives</brief_title>
  <official_title>Prevention of Clinical Onset of Type 1 Diabetes by Daily Administration of Metabolically Active Insulin in High Risk First Degree Relatives.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ-VUB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic administration of metabolically active insulin can prevent or delay clinical
      onset of diabetes in a high risk group of nondiabetic siblings as defined by positivity for
      autoantibodies against IA-2 (IA-2-A).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotheses:

      Primary: Prophylactic administration of metabolically active insulin can prevent or delay
      clinical onset of diabetes in a high risk group of nondiabetic siblings as defined by
      positivity for autoantibodies against IA-2 (IA-2-A).

      Secondary: 1) Untreated siblings with positivity for IA-2-A develop clinical diabetes
      significantly faster than untreated offspring with the same marker positivity. 2) Plasma
      proinsulin levels increase disproportionately before clinical onset of Type 1 diabetes both
      in siblings and offspring. 3) Prophylactic administration of metabolically active insulin
      reduces the plasma proinsulin/C-peptide ratio in non-diabetic antibody positive siblings and
      offspring. 4) Prophylactic administration of metabolically active insulin reduces the
      presence and/or levels of diabetes-associated autoantibodies directed against islet cell
      components.

      Endpoints: Fasting glycemia; fasting and stimulated plasma C-peptide and proinsulin values;
      islet cell autoantibodies; incidence of hypoglycemia; body weight gain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glycemia;</measure>
    <time_frame>2004</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting and stimulated plasma C-peptide and proinsulin values;</measure>
    <time_frame>2004</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>islet cell autoantibodies;</measure>
    <time_frame>2004</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>body weight gain.</measure>
    <time_frame>2004</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Diabetes, Type I</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actrapid HM</intervention_name>
    <description>56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sibling/offspring of a Type 1 diabetic patient

          -  in good general condition

          -  age 5-39 years

          -  fasting plasma glucose &lt;126 mg/dL AND an OGTT that is non-diabetic by 1997 ADA
             criteria (33):

               1. Normal glycemia:

                    -  fasting plasma glucose &lt; 110 mg/dL and

                    -  2 hour plasma glucose &lt; 140 mg/dL

               2. Impaired Fasting Glucose (IFG):

                    -  fasting plasma glucose 110-125 mg/dL and

                    -  2 hour plasma glucose &lt; 140 mg/dL

               3. Impaired Glucose Tolerance (IGT):

                    -  fasting plasma glucose &lt;110 mg/dL and

                    -  2 hour plasma glucose 140-199 mg/dL

          -  at least positive for IA-2-A

          -  absence of a protective DQ genotype: A4-B2/X or X/Y or X/X where X = A2-B3.3, A1-B1.9,
             A1-B1.2, A4-B3.1, A2-B2 or A4.23-B3.1 Y = A1-B1.1, A1-B2, A1-B1.AZH, A3-B2, A3-B3.1,
             A3-B3.3, A3-B4, A4-B4, A4.23-B4, A4-B3.2, A3-B1.1, A4-B3.3, A4-B1.1 or A4.23-B2 (32)

          -  cooperative and reliable subject (age ≥ 14 yrs) / parents (age &lt; 14 yrs) giving
             informed consent by signature; the patient/parents should be informed in sufficient
             detail on the content and procedure of the protocol, indicating potential risks of
             insulin therapy; early intervention with metabolically active insulin treatment should
             be identified as a clinical trial. Both parents should sign and agree with the
             protocol procedure.

        Exclusion Criteria:

          -  diabetes by 1997 ADA criteria (33):

               -  fasting plasma glucose ≥ 126 mg/dL, or

               -  2 hour plasma glucose ≥ 200 mg/dL

          -  donation of blood during the study or within one month prior to screening

          -  pregnancy or lactation in women

          -  use of inadequate anticonception by female patients of childbearing potential

          -  use of illicit drugs or overconsumption of alcohol (&gt; 3 beers/day) or history of drug
             or alcohol abuse

          -  being legally incapacitated, having significant emotional problems at the time of the
             study, or having a history of psychiatric disorders

          -  having received antidepressant medications during the last 6 months

          -  treatment with immune modulating or diabetogenic medication (such as corticosteroids)

          -  presently participating in another clinical study or having done so during the last 12
             months

          -  history of any illness that, in the opinion of the investigator, might confound the
             results of the study or pose additional risks to the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frans Gorus, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evy Vandemeulebroucke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis and Diabetes Research Center - Brussels Free University-VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Nephrology, UZ Gasthuisberg, Katholieke Universiteit Leuven -KUL</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Decochez K, Truyen I, van der Auwera B, Weets I, Vandemeulebroucke E, de Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia. 2005 Apr;48(4):687-94. Epub 2005 Mar 9.</citation>
    <PMID>15756536</PMID>
  </reference>
  <reference>
    <citation>Gorus FK, Weets I, Decochez K, van der Auwera BJ. [Preventative biology of type 1 diabetes: implications for clinical preventative studies]. Verh K Acad Geneeskd Belg. 2003;65(4):203-29; discussion 229-31. Review. Dutch.</citation>
    <PMID>14534938</PMID>
  </reference>
  <reference>
    <citation>Decochez K, De Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Weets I, Vandemeulebroucke E, Truyen I, Kaufman L, Schuit FC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetologia. 2002 Dec;45(12):1658-66. Epub 2002 Nov 12.</citation>
    <PMID>12488955</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>April 4, 2008</last_update_submitted>
  <last_update_submitted_qc>April 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. F Gorus</name_title>
    <organization>Free University Brussels</organization>
  </responsible_party>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

